Corebridge Financial Life Insurance Fit Review for Type 2 Diabetes

Research Snapshot

Why Corebridge Financial Qualified for This Study

Questions This Section Answers

• Is Corebridge Financial a good choice for Life Insurance for Type 2 Diabetes?
• Why did only two of seven AI platforms rank Corebridge Financial for Type 2 diabetes life insurance?

Corebridge Financial qualified because it was named by two of the seven platforms during the ranking stage, and because all seven platforms produced a full fit assessment for it once it was in scope. The ranking-stage mentions came from google (rank 3) and openai (rank 5), producing an average listed rank of 4.0 and a best listed rank of 3. That is a modest showing: five of the seven platforms did not name Corebridge in their ranked lists at all, even though several of them later assessed it as a good or mixed fit.

The split matters for buyers. Ranking-stage inclusion reflects which carriers a platform surfaced unprompted for the Type 2 diabetes prompt; the fit assessments reflect how each platform judged Corebridge once asked directly. Corebridge's fit ratings across the seven platforms were good (anthropic, google, grok), mixed (openai, deepseek, perplexity), and uncertain (kimi). No platform rated it poor, and no platform rated it unambiguously best-in-class.

Corebridge is a large U.S. life insurer with an A (Excellent) A.M. Best rating and more than $393–400 billion in assets ^[1]. That financial-strength context is relevant but does not establish diabetes-specific competitiveness. This review is scoped only to Life Insurance for Type 2 Diabetes; it is not a general company review. The broader Life Insurance for Type 2 Diabetes consensus index covers how Corebridge compares with other carriers.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Type 2 Diabetes

Questions This Section Answers

• Which Corebridge Financial product should a buyer with Type 2 diabetes choose: Select-a-Term or a permanent policy?
• Does Corebridge Financial's Agile Underwriting+ apply to term, indexed universal life, and guaranteed universal life applications?

The most relevant Corebridge offering for this use case is AIG Select-a-Term, paired with Corebridge Agile Underwriting+ (AU+) for eligible term, indexed universal life, and guaranteed universal life applications. Every platform in this study identified that same pairing, which makes it the one point of near-total agreement in the research.

Select-a-Term is a term life product with 18 available durations, described as spanning 10 through 35 years with intermediate periods ^[4]. One platform reported a 10-to-40-year range instead ^[7], which conflicts with the other sources and should be verified with the carrier. Term coverage is generally more affordable than permanent insurance and can match a defined coverage period such as a mortgage or income-replacement window ^[8].

Agile Underwriting+ is Corebridge's accelerated underwriting pathway. Corebridge states it is available for eligible term, indexed universal life, and guaranteed universal life applications ^[9]. Corebridge term materials describe possible no-exam underwriting and conversion without additional underwriting under stated limits ^[11]. One independent source reports that more than 60% of term applications qualify for AU+, while noting the final decision may still require labs or records ^[12]. Corebridge's own material states accelerated underwriting is best suited for applicants with good health histories and clean financial and criminal records ^[14].

Permanent options are limited to indexed universal life and guaranteed universal life. Corebridge does not offer traditional whole life insurance ^[15]. The exact IUL or GUL product intended by the ranking-stage recommendation was not specified by any platform (openai, factual uncertainty).

What the AI Platforms Agreed About

Questions This Section Answers

• What do AI platforms agree on about Corebridge Financial for Type 2 diabetes life insurance?
• Is Corebridge Financial's Select-a-Term conversion feature available without new medical underwriting?

Three findings drew broad, though not unanimous, agreement across the seven platforms.

First, product structure. All seven platforms identified Select-a-Term and Agile Underwriting+ as the relevant Corebridge offerings. Select-a-Term's 18 durations were confirmed by multiple independent reviews ^[16].

Second, conversion. Corebridge term materials state that full conversion may be available through the level-premium period or until age 70, whichever comes first, without new evidence of insurability or additional underwriting, subject to the specific policy ^[19]. Independent sources describe the same conversion window ^[20]. This is a strong point of agreement, but the exact conversion period length and procedures are not clearly defined in public sources (anthropic, factual uncertainty).

Third, financial strength. Corebridge holds an A (Excellent) rating from A.M. Best, A+ from Standard & Poor's, and A2 from Moody's, with over $393–400 billion in assets and 4.4 million policyholders ^[23]. No platform reported diabetes-specific claims issues.

A fourth, weaker point of agreement: several independent reviews describe Corebridge as historically strong or especially good for applicants with diabetes ^[27]. That agreement is notable but comes from review sites, not from Corebridge's own published underwriting rules.

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Is Corebridge Financial still competitive for impaired-risk diabetes underwriting in 2026?
• How much does Corebridge Financial cost per month for a buyer with Type 2 diabetes?

The platforms disagreed on fit rating and on how much weight to give Corebridge's diabetes reputation.

Fit ratings split three ways. Anthropic, google, and grok rated Corebridge a good fit. OpenAI, deepseek, and perplexity rated it mixed. Kimi rated it uncertain, noting that Corebridge did not appear in independent 2026 rankings of best life insurance for diabetics, where Banner Life, Nationwide, John Hancock, Prudential, and Mutual of Omaha were named instead ^[33].

Underwriting trajectory is disputed. One independent agent review reports that in 2024–2025 Corebridge has shown less aggressive offers for impaired risk, and that some previously favorable niches are now hit or miss ^[36]. Grok also noted the diabetes underwriting edge has narrowed in 2024–2025, with exact offers varying by profile (grok, factual uncertainty). No other platform confirmed a company-wide shift, so this may reflect regional variation or specific case types rather than a policy change.

Pricing is the largest gap. No diabetes-specific Corebridge premium, underwriting class, fee schedule, or guaranteed quote was publicly verifiable ^[38]. One independent source reports a Corebridge average annual premium of $272, almost 29% below an industry average of $382 ^[40], but that figure is not diabetes-specific and should not be used as a Type 2 diabetes estimate. Google reported that moderate control (A1C 7.5%–8.5%) typically produces Table 2–4 ratings representing a 50%–100% markup over standard rates, and that Corebridge is noted for lower table-rated markups than the industry average ^[41]. That is a single-platform, broker-sourced claim.

Other unresolved conflicts: the ranking label says "AIG Select-a-Term" while current Corebridge materials describe Select-a-Term as a Corebridge product and identify AIG Direct as transitioning toward Corebridge Direct, so exact branding and issuing company should be confirmed (openai, factual uncertainty). One platform reports the SimpliNow Choice platform often declines healthy applicants for vague reasons and is unreliable for complex health profiles ^[43]; Corebridge promotes it as real-time approval. The BBB rating picture is also split: the Corebridge Financial parent entity carries an F rating tied to 28 unanswered complaints, while the Corebridge Direct subsidiary holds A+ ^[45].

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What features does Corebridge Financial's Select-a-Term offer a buyer with Type 2 diabetes?
• Does Corebridge Financial offer living benefit riders on its term product for someone with diabetes complications?

Corebridge's use-case-relevant features cluster around term flexibility, accelerated underwriting, conversion, and riders.

Term duration flexibility. Select-a-Term offers 18 term-period choices, including durations from 10 through 35 years and intermediate periods ^[46]. Independent reviews call this a genuine market differentiator, since most competitors cap at 25–30 years ^[48].

Accelerated underwriting. Agile Underwriting+ may provide a path to approval without an exam, laboratory work, or attending physician statement for eligible term and permanent applications. Eligibility is not guaranteed, and applicants who do not qualify may undergo traditional underwriting ^[50]. One platform reported AU+ allows up to $1 million in coverage without a physical exam for healthy applicants aged 20–59 ^[52], while another reported no-exam availability up to $500,000 for ages 18–59 ^[53]. These limits conflict and should be verified. Corebridge's AU+ program pivots applications to full underwriting if the applicant does not qualify for Standard or better ratings ^[54], and requires a pivot to full physical measurements and labs if an automatic decision cannot be made ^[55].

Conversion. Select-a-Term is described as fully convertible to permanent coverage by end of the term conversion period or age 70, whichever is first, with no evidence of insurability required ^[56].

Living benefit riders. The Accelerated Access Solution rider provides income benefits without long-term care premiums ^[59]. The Quality of Life (QoL) Flex Term product includes a Chronic Illness Rider covering inability to perform two or more activities of daily living, plus Critical Illness and Terminal Illness riders ^[60]. One review notes Select-a-Term itself does not include chronic or critical illness riders ^[61], so riders may require the QoL Flex Term variant, which costs more.

Underwriting inputs. Corebridge describes use of third-party data including prescription history, Medical Information Bureau data, motor-vehicle records, credit reports, and medical databases in automated underwriting ^[50]. Traditional underwriting evaluates medical information, prescription history, physician statements, exams, laboratory results, lifestyle, and family history ^[62]. Public Corebridge materials do not disclose a Type 2 diabetes underwriting table or confirm how age at diagnosis, A1C, glucose control, insulin or other medications, complications, weight, or follow-up will affect eligibility and rate class ^[63].

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Corebridge Financial cost per month for Type 2 diabetes life insurance, and are there diabetes-specific surcharges?
• What contract terms, conversion deadlines, and cancellation rules apply to Corebridge Financial's Select-a-Term?

No diabetes-specific Corebridge premium, underwriting class, fee schedule, or guaranteed quote was publicly verifiable. Corebridge publishes illustrative prices for healthy, preferred applicants, which should not be used as a Type 2 diabetes estimate (openai, pricing summary). Pricing confidence was rated low by openai, deepseek, perplexity, and kimi, and moderate by anthropic and grok.

Known cost structure, as reported: premiums depend on age, coverage amount, term length, tobacco status, underwriting class, state, and individual medical profile (openai, known costs). Select-a-Term's monthly modal factor is reported at 8.45%, described as among the lowest in the market ^[65]. One broker source reports face amounts of $500,000+ have a top-two ranking in 70% of annual premium cases ^[66]. Minimum coverage is reported at $100,000 for term life, or $50,000 for ages 50+ in the Preferred class on some products (anthropic, known costs). Corebridge term rates are described as competitive but not the cheapest on the market ^[67].

Additional fees and riders: the Terminal Illness Accelerated Death Benefit is included at no extra cost on Select-a-Term. Living benefit riders (Accelerated Access Solution, Chronic Illness) are optional add-ons that increase premiums. A Return of Premium version of Select-a-Term is available in select term lengths and costs more than standard Select-a-Term (anthropic, additional fees). No diabetes-specific additional fee or surcharge was publicly disclosed, and potential examination, laboratory, medical-record, or attending-physician-statement costs were not clearly itemized in reviewed public materials (openai, additional fees).

Contract terms: Select-a-Term coverage ends at the selected term unless renewed or converted under the policy terms, and conversion availability and deadlines must be confirmed in the actual policy (openai, contract terms). Automatic renewal after term expires increases premiums annually to a maximum attainable age (anthropic, contract terms). Permanent-policy guarantees and values depend on the contract and payment pattern; buyers should obtain and review the policy illustration ^[68]. No verified surrender or cancellation penalty details were found for the relevant term product (perplexity, contract terms). Google reported a typical 30-day free look period allowing full premium refund upon early cancellation (google, contract terms).

Best Suited For

Questions This Section Answers

• Who is Corebridge Financial best suited for among buyers with Type 2 diabetes?
• Is Corebridge Financial a good fit for a buyer with well-controlled Type 2 diabetes on oral medication?

Corebridge is best suited for adults with well-controlled Type 2 diabetes who want flexible term coverage and are willing to complete full underwriting if the accelerated path does not apply.

Platforms converged on a similar profile: applicants with stable, well-controlled Type 2 diabetes, often diagnosed later in life, managing glucose with oral medications rather than insulin, and without complications (grok, best considered for; google, best considered for; anthropic, best considered for; deepseek, best considered for). Buyers who need custom term lengths to match a specific financial obligation are a strong match given the 18 available durations ^[70]. Buyers who may qualify for AU+ and want a faster application path are also a fit (openai, best considered for; anthropic, best considered for). Applicants willing to compare Corebridge underwriting and pricing with multiple carriers through an independent agent round out the profile (openai, best considered for).

Google specifically described the fit as applicants with well-managed Type 2 diabetes taking oral medications like Metformin who want highly flexible term lengths, and diabetic individuals who fall just outside standard rates and need competitive table-rated pricing (google, best considered for). That table-rating claim rests on a single independent broker source and should be treated as platform-reported rather than established.

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Corebridge Financial for Type 2 diabetes life insurance?
• Is Corebridge Financial a poor fit for insulin-dependent Type 2 diabetes or diabetes with complications?

Corebridge is probably not the best choice for applicants who need guaranteed acceptance, who have significant diabetes complications, or who prioritize customer service quality.

Applicants needing guaranteed acceptance or coverage without meaningful health underwriting are a poor fit (openai, probably not best for). Applicants whose diabetes includes significant complications, poor control, recent diagnosis, or inconsistent follow-up — and who need a carrier with clearly documented impaired-risk guidelines — are also poorly matched (openai, probably not best for). Grok stated AU+ is unavailable for insulin-dependent diabetes or certain complications, and that applicants needing no-exam coverage above $500,000 or instant decisions should look elsewhere (grok, probably not best for). Google reported that applicants with significantly complicated diabetes such as severe neuropathy or amputation, or poor medical compliance, are generally excluded from standard programs and AU+, potentially leading to premium loading, declines, or restriction to guaranteed-issue policies ^[72].

Buyers prioritizing customer service quality and satisfaction ratings should weigh the reported weaknesses: the Corebridge website offers only email and phone contact, with no live chat ^[74], and multiple independent reviews note below-average customer service ^[75]. Buyers requiring traditional whole life insurance must look elsewhere, since Corebridge does not offer that product type ^[76]. Buyers seeking permanent coverage as their primary product should note that IUL costs run higher than some competitors (anthropic, probably not best for). Buyers with complex health profiles routed to the SimpliNow Choice platform face a reported reliability concern ^[77].

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to Corebridge Financial for a buyer with insulin-dependent Type 2 diabetes?
• When should a buyer with Type 2 diabetes choose a guaranteed-issue or simplified-issue policy instead of Corebridge Financial?

Another option may be better in several defined situations.

When diabetes-specific underwriting experience, preferred impaired-risk treatment, or a documented A1C/insulin guideline is the main priority, choose another carrier or an independent broker's multi-carrier comparison (openai, better alternative when). Kimi reported that Corebridge did not appear in independent 2026 rankings of best life insurance for diabetics, where Banner Life, Nationwide, John Hancock, Prudential, and Mutual of Omaha were recognized instead ^[79]. Those platform-reported comparisons are the clearest signal that Corebridge is not the default first call for this use case.

When traditional underwriting is unavailable or declined, consider guaranteed-issue or simplified-issue alternatives, recognizing that coverage limits, waiting periods, and premiums may be less favorable (openai, better alternative when). When the applicant has uncontrolled Type 2 diabetes with elevated A1C, irregular monitoring, or non-compliance and requires maximum leniency, a carrier with explicit high-risk underwriting focus may be better (anthropic, better alternative when). When the applicant has multiple complex comorbidities such as diabetes plus heart disease or mental health conditions and needs specialized underwriting support, another carrier may be preferable (anthropic, better alternative when). When the buyer prefers direct online application without agent interaction, note that Corebridge requires agent involvement for most products (anthropic, better alternative when). When the buyer wants a diabetes-specific wellness program with premium discounts, John Hancock Aspire is described as purpose-built with a virtual clinic and fitness rewards (kimi, better alternative when). When the buyer wants the best chance at an individualized offer rather than an accelerated pathway, traditional full underwriting with several carriers may serve better (openai, better alternative when).

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Corebridge Financial before signing a Type 2 diabetes life insurance contract?
• Which legal entity issues the Corebridge Financial policy, and is the quoted product available in the buyer's state?

Verify these items before applying or signing.

1. Which legal insurance company will issue the policy in the buyer's state, and is the quoted product currently available there? (openai, questions to verify)
2. Does the applicant's Type 2 diabetes profile qualify for Agile Underwriting+, or will an exam, labs, or physician records be required? (openai, questions to verify; deepseek, questions to verify)
3. What A1C range, diagnosis age, insulin or medication use, complications, BMI or weight history, and follow-up records affect the underwriting class? (openai, questions to verify; perplexity, questions to verify)
4. Will the insurer obtain an attending physician statement, recent A1C results, medication history, or endocrinology records? (openai, questions to verify)
5. What tentative rate class and monthly premium apply before and after full underwriting? (openai, questions to verify)
6. Is the policy convertible, to which products, until what exact age or date, and are there conversion charges or restrictions? (openai, questions to verify; anthropic, questions to verify)
7. For permanent coverage, what premiums, policy charges, illustrated versus guaranteed values, surrender charges, and lapse risks apply? (openai, questions to verify)
8. Are living-benefit or chronic-illness riders available, and what exclusions, qualification standards, and charges apply? (openai, questions to verify)
9. What external data may be used in accelerated underwriting, and how can the applicant challenge inaccurate data or an adverse decision? (openai, questions to verify)
10. What is the maximum coverage available through Agile Underwriting without a medical exam for the applicant's age and health profile? (kimi, questions to verify)
11. If declined or rated poorly, what guaranteed-issue or simplified-issue alternatives does Corebridge offer? (kimi, questions to verify)
12. What is the current A.M. Best rating specifically for the issuing insurance entity? (kimi, questions to verify)

Final AI Consensus Verdict

Corebridge Financial is a mixed-to-good fit for Life Insurance for Type 2 Diabetes, not a consensus best choice. Two of seven platforms named it in the ranking stage at an average rank of 4.0. Fit ratings split across good, mixed, and uncertain, with no platform calling it poor and none calling it clearly superior.

The case for Corebridge rests on Select-a-Term's 18 durations, Agile Underwriting+ for eligible applications, conversion without new underwriting within the stated window, and independent reviews describing historically competitive diabetes underwriting. The case against rests on the absence of published diabetes-specific underwriting criteria, rate classes, or premiums; conflicting no-exam coverage limits; a reported 2024–2025 moderation in impaired-risk offers; below-average customer service signals; and non-appearance in independent 2026 diabetic insurance rankings.

The practical verdict: obtain a fully underwritten quote from Corebridge and compare it against multiple carriers experienced in diabetic-risk underwriting before committing. Platform agreement in this study reflects how AI systems summarized available public information; it does not prove product quality or predict any individual underwriting outcome.

How This Review Was Produced

This review was produced from a fixed research run dated 2026-09-22 covering seven AI platforms: anthropic (claude-haiku-4-5-20251001), deepseek (deepseek-v4-flash), google (gemini-3.5-flash), grok (x-ai/grok-4.3), kimi (moonshotai/kimi-k2.6), openai (gpt-5.6-luna), and perplexity (perplexity/sonar). Each platform answered the same Type 2 diabetes life insurance prompt and produced a fit assessment for Corebridge Financial. Ranking statistics count only platforms that named Corebridge during ranking discovery; fit assessments were collected from all seven.

All platform outputs carry a verification status of platform-reported, not independently verified. Citations in this article map to the platform that supplied them. Company-owned sources are labeled as such in the Sources section and are distinguished from independent reviews and government material throughout.

Methodology Limitations

Several limitations apply. Platform-reported research dates differ from the authoritative run date: deepseek reported 2026-01-15 while the run date is 2026-09-22, and deepseek ran with search disabled, so its claims require explicit verification before being treated as current. The supplied URLs were collected from platform responses and were not independently validated by the writer stage. Citations are platform-reported evidence, not independently verified facts.

No diabetes-specific Corebridge underwriting criteria, rate classes, or premiums were publicly verifiable, so pricing conclusions are limited. Conflicting product names, coverage limits, and capability claims were left unresolved rather than guessed. The ranking label "AIG Select-a-Term" conflicts with current Corebridge branding, and the exact IUL or GUL product intended by the ranking-stage recommendation was never specified. One cited underwriting guide is distributed by a broker rather than Corebridge directly. Platform agreement in this study does not establish product quality, and no personal testing, customer experience, or independent verification was performed.